Robert Cerwinski, JD, Partner at Goodwin, discusses the “big 3” biologics for inter partes review: Herceptin, Rituxan, and Humira.
Transcript:
What are some recent trends in [Patent Trial and Appeal Board, PTAB] decisions concerning biologics and biosimilars?
We see that biosimilar manufacturers have really embraced the availability of [inter partes review, IPRs] as a mechanism. Well before the biosimilar applications are actually submitted to FDA, we see that biosimilar manufacturers are really trying to clear a path with key patents well before they actually get to FDA. That’s a definite trend that we see in biosimilars. We had expected that IPRs would be important to biosimilar manufacturers, given the sheer number of patents and the variety of patents that typically cover reference products, especially products like Humira where there is a veritable patent thicket protecting it, and indeed that’s what we’ve seen. Most of the IPRs that have been filed to date have really centered on 3 products: Herceptin, Rituxan, and Humira. So, 3 of the biggest biologics that are really amenable to biosimilar applications at this point. Over a dozen of IPRs have been filed with respect to each of these products and the patents that cover them. Those are the big 3 for IPRs.
In terms of what’s actually happening at the PTAB with these biologic-related IPRs, we see that the rate of success for petitioners has been somewhat lower than what we’ve observed for petitioners generally. It’s a complex area of technology and we’re seeing that the PTAB is being very careful and meticulous in its approach to institution decisions as well as its approach to final determinations. So we’re seeing a lower rate of institution for biosimilar-related IPRs than in general. For those petitions that are instituted, we’re seeing a somewhat lower rate of invalidation after final determination. And in terms of patents that fare better or worse, if you are a petitioner in the PTAB, we see that method-of-use patents, so patents that cover approved indications, institution is granted somewhat more often for those kinds of patents than for composition patents or formulation patents. The data set isn’t very large for this yet, but we do something of trend in that respect, and that holds true in final determinations as well; we see that the PTAB, at least currently, has been more willing to hold method-of-use patents invalid. I think we are also seeing—I use the word “meticulous”—I think the PTAB is really trying hard to get these petitions resolved correctly. They are being—I use the word “sticklers”—they are holding everybody to the rules and they are holding everybody to their burdens of proof in these petitions pretty rigorously.
Budget Impact Analysis of Biosimilar Natalizumab in the US
Projected savings from biosimilar natalizumab were $452,611 over 3 years, driven by decreased drug acquisition costs and a utilization shift from reference to biosimilar natalizumab.
Biosimilars in America: Overcoming Barriers and Maximizing Impact
July 21st 2024Join us as we explore the complexities of the US biosimilars market, discussing legislative influences, payer and provider adoption factors, and strategies to overcome industry challenges with expert insights from Kyle Noonan, PharmD, MS, value & access strategy manager at Cencora.
Switching Patterns Highlight Nocebo Effect in European Patients Using Amgevita
July 23rd 2024About half of the patients in a European study who transitioned from reference adalimumab to a biosimilar version stayed on the biosimilar at the 1-year mark. However, researchers warned about a possible nocebo effect resulting in some patients switching back to the originator.
Biosimilars Oncology Roundup for June 2024—Podcast Edition
July 7th 2024On this episode of Not So Different, we review biosimilar news coming out of June, with clinical trial results from conferences and a study showcasing how to overcome economic and noneconomic barriers to oncology biosimilars.
Hesitancy in MENA Nations to Adopt WHO Biosimilar Guidelines Hinders Market Development
July 17th 2024The World Health Organization’s (WHO) new guidelines for biosimilar approvals aim to save time and money for manufacturers in the Middle East and North Africa (MENA), but hesitancy among nations to adopt the guidelines is stifling market development of biosimilars.